CA2555050A1 — 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor
Assigned to Boehringer Ingelheim International GmbH · Expires 2005-09-15 · 21y expired
What this patent protects
The invention relates to substituted xanthines of general formula (I), where in R is such as defined in claim 1, and to the tautomers, stereoisomers, mixtur es and the salts thereof, said products exhibiting precious pharmacological properties, in particular an inhibiting effect …
USPTO Abstract
The invention relates to substituted xanthines of general formula (I), where in R is such as defined in claim 1, and to the tautomers, stereoisomers, mixtur es and the salts thereof, said products exhibiting precious pharmacological properties, in particular an inhibiting effect on a dipeptidylpeptidasa-IV (DPP-IV) enzyme activity.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.